Put in a “Ca2+ll” to Acute Myeloid Leukemia - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Cells Year : 2022

Put in a “Ca2+ll” to Acute Myeloid Leukemia


Acute myeloid leukemia (AML) is a clonal disorder characterized by genetic aberrations in myeloid primitive cells (blasts) which lead to their defective maturation/function and their proliferation in the bone marrow (BM) and blood of affected individuals. Current intensive chemotherapy protocols result in complete remission in 50% to 80% of AML patients depending on their age and the AML type involved. While alterations in calcium signaling have been extensively studied in solid tumors, little is known about the role of calcium in most hematologic malignancies, including AML. Our purpose with this review is to raise awareness about this issue and to present (i) the role of calcium signaling in AML cell proliferation and differentiation and in the quiescence of hematopoietic stem cells; (ii) the interplay between mitochondria, metabolism, and oxidative stress; (iii) the effect of the BM microenvironment on AML cell fate; and finally (iv) the mechanism by which chemotherapeutic treatments modify calcium homeostasis in AML cells.
Fichier principal
Vignette du fichier
cells-11-00543-v2.pdf (2.55 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03562726 , version 1 (09-02-2022)



Clara Lewuillon, Marie-Océane Laguillaumie, Bruno Quesnel, Thierry Idziorek, Yasmine Touil, et al.. Put in a “Ca2+ll” to Acute Myeloid Leukemia. Cells, 2022, 11 (3), pp.543. ⟨10.3390/cells11030543⟩. ⟨inserm-03562726⟩
42 View
62 Download



Gmail Facebook X LinkedIn More